The present study suggests that anti-PD-1 and anti-PD-L1 agents have similar efficacy and safety in ES-SCLC when delivered in combination with platinum-based doublet chemotherapy as first-line treatment. This evidence concerns the gene PDCD1 and small cell lung carcinoma.